The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy

Kokolakis, Georgios; Ghoreschi, Kamran

doi:10.3390/jcm12010035

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-17A-producing T cells. This may explain the clinical observation that simultaneous blockade of IL-17A and IL-17F resulted in successful treatment of patients who failed to respond to selective anti IL17A therapy before ( 41 ). Besides, IL-17F may also play a role in the recurrent course of psoriasis ( 42 ).…”

Section: The Il-17 Cytokine Family – An Updatementioning

confidence: 97%

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies

Brembilla¹,

Boehncke

2023

Front. Immunol.

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory skin disease, associated with substantial comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived IL-23, and mediating their effects via IL-17A, are believed to be central effector cells in psoriasis. This concept is underlined by the unprecedented efficacy of therapeutics targeting this pathogenetic axis. In recent years, numerous observations made it necessary to revisit and refine this simple “linear” pathogenetic model. It became evident that IL-23 independent cells exist that produce IL-17A, that IL-17 homologues may exhibit synergistic biological effects, and that the blockade of IL-17A alone is clinically less effective compared to the inhibition of several IL-17 homologues. In this review, we will summarize the current knowledge around IL-17A and its five currently known homologues, namely IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) and IL-17F, in relation to skin inflammation in general and psoriasis in particular. We will also re-visit the above-mentioned observations and integrate them into a more comprehensive pathogenetic model. This may help to appreciate current as well as developing anti-psoriatic therapies and to prioritize the selection of future drugs’ mode(s) of action.

show abstract

Section: The Il-17 Cytokine Family – An Updatementioning

confidence: 97%

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies

Brembilla¹,

Boehncke

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Psoriasis is one of the most common erythematous scaly diseases in dermatology. It is characterized by sharply defined patches with silvery scales on the surface accompanied by systemic manifestations ( 1 ). The etiopathogenesis is complex, and it is currently believed to be a chronic inflammatory disease mediated by the immune system against a genetic background ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Paradoxical reaction to IL-17A inhibitor: a case report and literature review

Ren,

Deng,

Guo

et al. 2024

Front. Med.

View full text Add to dashboard Cite

ObjectiveA case of pustular psoriasis after treatment with secukinumab in a patient with plaque psoriasis is reported, which is the first case in China. To summarize the clinical characteristics of patients who developed the rare paradoxical reaction and treatment options received IL-17A antagonist therapy, we conducted a further literature review.MethodsData were analyzed from a patient with plaque psoriasis who developed pustular psoriasis after treatment with secukinumab. A comprehensive review of relevant domestic and international literature was conducted, focusing on cases that met our inclusion criteria for analysis and synthesis.ResultsAnti IL-17A therapy may lead to type conversion, with reported cases more prevalent in women and varying in onset time, predominantly involving palmoplantar pustulosis.ConclusionGiven the increasing use of IL-17A antagonists in psoriasis treatment, it is crucial to monitor for rare adverse reactions, including the paradoxical induction of pustular psoriasis.

show abstract

Biological therapy for psoriatic arthritis: current state and future perspectives

Boboryko,

Olejnik-Wojciechowska,

Baranowska

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy

Cited by 6 publications

References 16 publications

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies

Paradoxical reaction to IL-17A inhibitor: a case report and literature review

Biological therapy for psoriatic arthritis: current state and future perspectives

Contact Info

Product

Resources

About